National Oesophago–Gastric Cancer Audit

NCIN Upper GI Clinical Leads Workshop

19 October 2011

First O-G Cancer Audit (OG1)

- Patients diagnosed between 1 October 2007 and 30 June 2009 eligible for inclusion

- Audit collected data on:
  - 16,264 English patients and 1,015 Welsh patients

- Three Annual Reports
  - Routes to diagnosis and staging investigations
  - Planned treatments for different patient groups
  - Curative surgical outcomes
  - Palliative therapies

The Next National Audit

- Officially began in June 2011
- Covers patients diagnosed from 1 April 2011
- Similar scope to first O-G cancer audit
  - Extended to patients with high-grade dysplasia
  - Scotland and N. Ireland may participate
- Not collecting patient-reported outcomes

Similar audit questions

- Investigate extent of differences among NHS services in England and Wales
  - Clinical (pre-treatment) staging investigations
  - Planned curative / palliative treatments for similar patient groups
  - Use of curative modalities for suitable patients, such as neoadjuvant chemotherapy
  - Use of oncological and endoscopic/radiological palliative services among palliative patients
  - Outcomes of care

Project team

AUGIS — Richard Hardwick

British Society of Gastroenterology — Stuart Riley

RCR The Royal College of Radiologists — Tom Crosby

RCS ADVANCING SURGICAL STANDARDS — Zubir Ahmed, Oliver Groene, David Cromwell

The Information Centre knowledge for care — Kimberley Greenaway, Rose Napper

First Year of the Audit

- Undertake organisational audit
- (Re)start collection of OG1 prospective dataset
- Refine prospective dataset

- First Annual Report
  - Results of the organisational audit
  - Longer term outcomes of patients diagnosed in the original Audit data collection period

Organisational Audit

- Topics
  - Referral policies within Cancer Networks
  - Availability of palliative care services
  - How are High Grade Dysplasia patients managed?
  - How are private patients handled in MDTs?
  - How many trusts ask patients to consent for audits?

- Questionnaires will be sent to Networks and NHS trusts

Refinement of dataset

- "Tweaks" rather than wholesale change for patients with O-G cancer, eg:
  - Allow entry on TNM version 7
  - Add "No complication" to surgical complications item
  - Add item for patients finishing neoadjuvant therapy who does not proceed to resection
  - Make some items mandatory – resection margins
- Aim to reduce items by using other data sources
- Consult on changes with stakeholders

Example: Longitudinal margins

		Oesophageal Resections	Positive margin	(%)
T stage	0 or 1	438	7	(1.6%)
	2	385	22	(5.7%)
	3	1,017	79	(7.8%)
	4	52	12	(23.1%)
N stage	0	862	30	(3.5%)
	1	1,030	90	(8.7%)
Nodes ratio	0.0 to 0.1	365	20	(5.5%)
	0.1 to 0.2	246	13	(5.3%)
	0.2 to 0.3	165	15	(9.1%)
	0.3 plus	254	42	(16.5%)

High Grade Dysplasia

- Cases in England – 1,350 (45 per network)

- Keep audit questions simple
  - What %HGD patients go on surveillance programs?
  - Are hospitals selecting similar patients for EMR, ablation or oesophagectomy?
  - What are the 1-year survival rates for patients with HGD undergoing resection?

- Add few new data items

Second / third years

- Commence collection of refined dataset
  - Switch over in June 2012
- Link collected data to routine datasets
  - ONS, HES/PEDW, and ICNARC
  - Radiotherapy (RTDS)
  - Other datasets when ready (eg, chemotherapy)
- Results published in Annual Reports

Conclusion

- Audit has started!

- Please encourage hospital participation
  - Using OG1 dataset this year not a waste of time
  - Will allow comparison with earlier results
  - “New” dataset will be refinement

- Publish revised dataset in early 2012
  - Allow time for software upgrades